Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIPI6398 in schizophrenia (phase 2)
CTR20233362Phase 2Completed
- Sponsor
- Zhongze Therapeutics
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ZZ6398 in schizophrenia, sponsored by Zhongze Therapeutics. Started Oct 2023; status: completed.
02
Drugs
ZZ6398
03
Conditions
schizophrenia
Beyond the preview
Go deeper on CTR20233362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233362.